The US Centers for Medicare & Medicaid Services granted reimbursement for Illumina’s TruSight Oncology Comprehensive assay at $2,989.55 per test, effective Jan. 1, 2026. Illumina said the FDA‑cleared comprehensive genomic profiling test interrogates more than 500 genes (DNA) plus key RNA fusions and splice variants to inform oncology treatment decisions. Illumina framed the CMS decision as reducing adoption barriers for comprehensive genomic profiling and enabling broader precision‑oncology access in clinical care.